These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 30159669)

  • 1. Four-year follow-up of patients with imatinib-resistant or intolerant chronic myeloid leukemia receiving dasatinib: efficacy and safety.
    Huang X; Jiang Q; Hu J; Li J; Jin J; Meng F; Shen Z; Liu T; Wu D; Wang J; Wang J
    Front Med; 2019 Jun; 13(3):344-353. PubMed ID: 30159669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Study on efficiency and safety of dasatinib in Chinese patients with chronic myelogenous leukemia who are resistant or intolerant to imatinib].
    Huang XJ; Hu JD; Li JY; Jin J; Meng FY; Shen ZX; Liu T; Wu DP; Wang JM; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2012 Nov; 33(11):889-95. PubMed ID: 23363742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.
    Hochhaus A; Baccarani M; Deininger M; Apperley JF; Lipton JH; Goldberg SL; Corm S; Shah NP; Cervantes F; Silver RT; Niederwieser D; Stone RM; Dombret H; Larson RA; Roy L; Hughes T; Müller MC; Ezzeddine R; Countouriotis AM; Kantarjian HM
    Leukemia; 2008 Jun; 22(6):1200-6. PubMed ID: 18401416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial.
    Gore L; Kearns PR; de Martino ML; Lee ; De Souza CA; Bertrand Y; Hijiya N; Stork LC; Chung NG; Cardos RC; Saikia T; Fagioli F; Seo JJ; Landman-Parker J; Lancaster D; Place AE; Rabin KR; Sacchi M; Swanink R; Zwaan CM
    J Clin Oncol; 2018 May; 36(13):1330-1338. PubMed ID: 29498925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.
    Shah NP; Rousselot P; Schiffer C; Rea D; Cortes JE; Milone J; Mohamed H; Healey D; Kantarjian H; Hochhaus A; Saglio G
    Am J Hematol; 2016 Sep; 91(9):869-74. PubMed ID: 27192969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy of dasatinib in treatment of imatinib-resistant BCR/ABL positive leukemia].
    Zhu Y; Pan LQ; Qian SX; Song P; Yu H; Zhang SJ; Ge Z; Hong M; Tian T; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):581-6. PubMed ID: 23815902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia.
    Naqvi K; Jabbour E; Skinner J; Anderson K; Dellasala S; Yilmaz M; Ferrajoli A; Bose P; Thompson P; Alvarado Y; Jain N; Takahashi K; Burger J; Estrov Z; Borthakur G; Pemmaraju N; Paul S; Cortes J; Kantarjian HM
    Cancer; 2020 Jan; 126(1):67-75. PubMed ID: 31553487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of molecular response at 1 or 3 months after the initiation of dasatinib treatment can predict an improved response to dasatinib in imatinib-resistant or imatinib-intolerant Japanese patients with chronic myelogenous leukemia during the chronic phase.
    Inokuchi K; Kumagai T; Matsuki E; Ohashi K; Shinagawa A; Hatta Y; Takeuchi J; Yoshida C; Wakita H; Kozai Y; Shirasugi Y; Fujisawa S; Iwase O; Yano S; Okamoto S; Oba K; Sakamoto J; Sakamaki H
    J Clin Exp Hematop; 2014; 54(3):197-204. PubMed ID: 25501110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second-line Dasatinib Therapy Improved Compliance and Deep Molecular Responses in Imatinib-intolerant Chronic Myeloid Leukemia Patients.
    Markovic U; Bulla A; Leotta S; Stella S; Consoli ML; TambÈ L; Conticello C; DI Raimondo F; Stagno F
    Anticancer Res; 2020 Sep; 40(9):5313-5317. PubMed ID: 32878823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
    Shiseki M; Yoshida C; Takezako N; Ohwada A; Kumagai T; Nishiwaki K; Horikoshi A; Fukuda T; Takano H; Kouzai Y; Tanaka J; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
    Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia.
    Khoury HJ; Goldberg SL; Mauro MJ; Stone RM; Deininger MW; Bradley-Garelik MB; Mohamed H; Guilhot F
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):341-349.e1. PubMed ID: 27133948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium.
    Zwaan CM; Rizzari C; Mechinaud F; Lancaster DL; Lehrnbecher T; van der Velden VH; Beverloo BB; den Boer ML; Pieters R; Reinhardt D; Dworzak M; Rosenberg J; Manos G; Agrawal S; Strauss L; Baruchel A; Kearns PR
    J Clin Oncol; 2013 Jul; 31(19):2460-8. PubMed ID: 23715577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
    Abbott BL
    Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dasatinib in imatinib-resistant or -intolerant CML patients: data from the clinical practice of 6 hematological centers in the Czech Republic.
    Klamova H; Faber E; Zackova D; Markova M; Voglova J; Cmunt E; Novakova L; Machova-Polakova K; Moravcova J; Dvorakova D; Michalova K; Brezinova J; Oltova A; Jarosova M; Cetkovsky P; Indrak K; Mayer J
    Neoplasma; 2010; 57(4):355-9. PubMed ID: 20429627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily.
    Saglio G; Hochhaus A; Goh YT; Masszi T; Pasquini R; Maloisel F; Erben P; Cortes J; Paquette R; Bradley-Garelik MB; Zhu C; Dombret H
    Cancer; 2010 Aug; 116(16):3852-61. PubMed ID: 20564086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy and safety of domestic dasatinib as second-line treatment for chronic myeloid leukemia patients in the chronic phase].
    Chen YL; Wang L; Yan GL; Yang ZZ; Huang ZP; Zhang YS; Zhao Z; Wan CC; Bao Y; Xiang H; Yin H; Chen LF; Xiong YY; Meng L; Li WM
    Zhonghua Xue Ye Xue Za Zhi; 2019 Feb; 40(2):98-104. PubMed ID: 30831623
    [No Abstract]   [Full Text] [Related]  

  • 17. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study.
    Shah NP; Guilhot F; Cortes JE; Schiffer CA; le Coutre P; Brümmendorf TH; Kantarjian HM; Hochhaus A; Rousselot P; Mohamed H; Healey D; Cunningham M; Saglio G
    Blood; 2014 Apr; 123(15):2317-24. PubMed ID: 24569263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial.
    Cortes JE; Saglio G; Kantarjian HM; Baccarani M; Mayer J; Boqué C; Shah NP; Chuah C; Casanova L; Bradley-Garelik B; Manos G; Hochhaus A
    J Clin Oncol; 2016 Jul; 34(20):2333-40. PubMed ID: 27217448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase.
    Fava C; Kantarjian HM; Jabbour E; O'Brien S; Jain N; Rios MB; Garcia-Manero G; Ravandi F; Verstovsek S; Borthakur G; Shan J; Cortes J
    Blood; 2009 May; 113(21):5058-63. PubMed ID: 19282457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Analysis of the efficacy and influencing factors of nilotinib or dasatinib as second- or third-line treatment in patients with chronic myeloid leukemia in the chronic phase and accelerated phase].
    Yuan T; Lai YY; Qin YZ; Shi HX; Huang XJ; Hou Y; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2020 Feb; 41(2):93-99. PubMed ID: 32135623
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.